Health Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis).1 The approval broadens the indication for AMVUTTRA®, which now becomes the first and only RNAi therapeutic authorized by Health Canada for the treatment of both the cardiomyopathy manifestations of TTR amyloidosis and stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis.2

Cardiomyopathy with wtATTR or hATTR amyloidosis (also referred to as ATTR-CM) is a devastating, progressive and ultimately fatal condition affecting over 300,000 people worldwide.3,4 In Canada, the disease is under-recognized and under-diagnosed as symptoms tend to be associated with other conditions.5 There is no cure for ATTR-CM, which is caused by the deposition of misfolded transthyretin (TTR) fibrils (malformed proteins) that build up primarily in your heart and elsewhere in the body. This makes it harder for the heart to pump blood throughout the body, which can cause irreversible damage, and lead to heart failure.6 Life expectancy for patients with ATTR-CM is currently two to five years after diagnosis, highlighting the importance of early and accurate detection to slow disease progression.7